{
    "clinical_study": {
        "@rank": "53735", 
        "arm_group": {
            "arm_group_label": "primary", 
            "description": "subjects who are 18 years or older, who have minimal residual disease detected by PCR at a level of 1/10-3 or higher, who are free form allogeneic stem cell transplantation until hematological relapse or until 18 months after minimal residual disease detection (whichever comes first)"
        }, 
        "brief_summary": {
            "textblock": "A retrospective analysis of historical data looking at relapse free survival and overall\n      survival rates in adult philadelphia negative B-pre-cursor acute lymphoblastic leukemia\n      patients."
        }, 
        "brief_title": "Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Lymphoblastic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Neoplasm, Residual"
            ]
        }, 
        "detailed_description": {
            "textblock": "A retrospective observational study reviewing historical survival data (relapse free\n      survival and overall survival) for adult patients who have philadelphia negative B-precursor\n      acute lymphoblastic leukemia, and are in complete hematological remission with minimal\n      residual disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with Philadelphia-negative B-Precursor Acute Lyphmoblastic Leukemia in\n             complete hematological remission defined as less than 5% blasts in bone marrow after\n             at least 3 intensive chemotherapy blocks (i.e. any standard or investigational\n             regimen according to adult protocols as long as 3 age appropriate chemotherapy blocks\n             were given, this also includes relapse treatment\n\n          -  detection of minimal residual disease (molecular failure or molecular relapse) at a\n             level of greater than or equal to 10*(-4) by PCR or greater than or equal to 10*(-3)\n             by flow cytometry at a reference lab\n\n          -  Age 15 or greater at time of initial diagnosis with acute lymphoblastic leukemia. For\n             patients aged 15-17 treatment according to adult protocols is required\n\n          -  Initial diagnosis in the year 2000 or later\n\n          -  History of acute lymphoblastic leukemia treatment (including response to first\n             therapy, number of prior relapses) is available\n\n          -  Relapse status and disease follow up after timepoint of minimal residual disease\n             detection is available\n\n        Exclusion Criteria:\n\n          -  Patients with extramedullary disease at timepoint of minimal residual disease\n             detection\n\n          -  Use of Blinatumomab within 18 months of minimal residual disease detection\n\n          -  Allogeneic hematopoietic stem cell transplantation prior to minimal residual disease\n             detection at the required level"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "adult acute lymphoblastic leukemia"
            }
        }, 
        "enrollment": {
            "#text": "310", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02010931", 
            "org_study_id": "20120148"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 29, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brno", 
                        "country": "Czech Republic", 
                        "zip": "625 00"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris Cedex 10", 
                        "country": "France", 
                        "zip": "75475"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt am Main", 
                        "country": "Germany", 
                        "zip": "60590"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "zip": "40138"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "zip": "00161"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Venezia", 
                        "country": "Italy", 
                        "zip": "30174"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gliwice", 
                        "country": "Poland", 
                        "zip": "44-101"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "125167"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Badalona", 
                        "country": "Spain", 
                        "state": "Catalu\u00f1a", 
                        "zip": "08916"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "NW3 2PF"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Czech Republic", 
                "France", 
                "Germany", 
                "Italy", 
                "Poland", 
                "Russian Federation", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "A Retrospective Analysis of Hematological Relapse Free Survival and Overall Survival in Adult Patients With Philadelphia-Negative B-Precursor Acute Lymphoblastic Leukemia in Complete Hematological Remission With Minimal Residual Disease", 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: NRES Committee South Central - Southampton A", 
                "Russia: Ethics committee of State Institution Hematological Scientific Center Russian Academy of Medical Sciences", 
                "Czech Republic: Ethics Committee", 
                "Czech Republic: State Institute for Drug Control", 
                "France: Comit\u00e9 consultatif sur le traitement de l'information en mati\u00e8re de recherche dans le domaine de la sant\u00e9", 
                "France: CNIL (Commission Nationale de L'informatique et Libert\u00e9)", 
                "France: CNOM (Conseil National de L'ordre des m\u00e9decins)", 
                "Germany: Ethics committee of the Bavarian State Board of Physicians", 
                "Germany: Ethic commission of the faculty of medicine,  University of Frankfurt", 
                "Spain: Ethics Committee - Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica del Hospital Universitario Germans Tr\u00edas i Pujol", 
                "Spain: Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios", 
                "Italy: Ethics Committee", 
                "Netherlands:  Independent Ethics Committee", 
                "Poland: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "to estimate the hematological relapse free survival in patients who are 18 years or older, who have minimal residual disease detected by PCR at a level of 1/10-3 or higher, who are free form allogeneic stem cell transplantation until hematological relapse or until 18 months after minimal residual disease detection (whichever comes first)", 
            "measure": "hematological relapse free survival", 
            "safety_issue": "No", 
            "time_frame": "Approximately 18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02010931"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "to estimate the hematological relapse free survival in patients who are 15 years or older, who have minimal residual disease regardless of detection method, with or without stem cell transplantation within18 months of minimal residual disease detection", 
                "measure": "hematological relapse free survival", 
                "safety_issue": "No", 
                "time_frame": "Approximately 18 months"
            }, 
            {
                "description": "to estimate overall survival in the 2 sets of patients described in the primary outcome measure, and the first secondary outcome measure.", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "Approximately 18 months"
            }, 
            {
                "description": "to estimate the mortality rate (proportion) at 100 days following allogeneic stem cell transplantation in patients who received an allogeneic stem cell transplantation within 18 months after minimal residual disease detection", 
                "measure": "mortality rate", 
                "safety_issue": "No", 
                "time_frame": "100 days following allogeniec stem cell transplantation"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "collaborator": {
                "agency": "European EWALL study groups", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}